Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

April 10, 2024

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

April 10, 2024

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

April 04, 2024

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Analyst Expectations for Pharvaris's Future ↗

December 07, 2023

Via Benzinga

March 18, 2024

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

March 06, 2024

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

March 05, 2024

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

February 22, 2024

Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks

Pharvaris Announces Extraordinary Meeting of Shareholders

February 16, 2024

Pharvaris to Present at the WSAAI Annual Meeting 2024

January 26, 2024

The company is working on a treatment for swelling attacks associated with a genetic disease.

Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision ↗

January 22, 2024

Via Investor's Business Daily

FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps ↗

January 22, 2024

Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment.

Via Benzinga

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

January 22, 2024

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

January 05, 2024

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

December 08, 2023

U.S. stocks traded mixed toward the end of trading on Wednesday. The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51. The S&P 500 also fell, dropping, 0.05% to 4,564.73.

Gold Moves Higher; Campbell Soup Earnings Top Expectations ↗

December 06, 2023

Via Benzinga

Topics Stocks

Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

December 06, 2023

Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results.

Via Benzinga

Turnaround For Pharvaris Since FDA Clinical Hold - Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks ↗

December 06, 2023

Pharvaris NV (NASDAQ: PHVS) released topline data from the CHAPTER-1 Phase 2 study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful...

Via Benzinga

Crude Oil Down 4%; Pharvaris Shares Spike Higher ↗

December 06, 2023

U.S. stocks traded mostly flat midway through trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.01% to 36,126.75 while the NASDAQ rose 0.03% to 14,233.77. The S&P 500 also fell,...

Via Benzinga

Topics Stocks

AMD Stock Alert: What to Expect From Advanced Micro Devices ‘Advancing AI’ Event ↗

December 06, 2023

Advanced Micro Devices stock is climbing higher on Wednesday as AMD investors prepare for the company's Advancing AI event today.

THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday ↗

Topics Artificial Intelligence

December 06, 2023

U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday.

Via Benzinga

Topics Stocks

Shopify (SHOP) Stock Falls Following Analyst Downgrade ↗

December 06, 2023

Shopify stock is taking a beating on Wednesday after shares of SHOP were hit with a downgrade from Wedbush analyst Scott Devitt.

Pharvaris stock is rising higher on Wednesday following news of an underwritten offering for PHVS shares and pre-funded warrants.

Why Is Pharvaris (PHVS) Stock Up 36% Today? ↗

December 06, 2023

U.S. stocks traded higher this morning, following the release of economic reports on Wednesday. Following the market opening Wednesday, the Dow traded up 0.21% to 36,200.86 while the NASDAQ rose 0.28%...

US Stocks Higher; Private Payrolls Rise By 103,000 In November ↗

December 06, 2023

Via Benzinga

Topics Stocks

Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants

December 06, 2023

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

December 06, 2023

Pharvaris to Present at the GA²LEN UCARE Conference 2023

November 30, 2023

Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

November 15, 2023

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

November 09, 2023